CD274 and neoplasm: In Checkmate 141, using a cut point of ≥1% tumor membranous PD-L1 expression, there was a greater reduction in the risk of death with Nivolumab versus standard therapy in positive patients (HR for death: 0.55; 95% CI: 0.36–0.83) compared to PD-L1 negative (HR for death: 0.89; 95% CI: 0.54–1.45).